Fairvalue-Calculator Fairvalue-Calculator
EN DE

One Health Group (OHGR) Fair Value & Analysis

Healthcare · GB · Market cap 34.1M GBX

Pricep2.47
Fair Valuep2.37
Upside-4.0%
Quality87/100
Evidence: Medium Range p1.86 – p2.88

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

One Health Group (OHGR) currently trades at p2.47, while our model-based Fair Value estimate is p2.37 — implying the stock looks roughly 4.0% overvalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

One Health Group Plc provides diagnosis and treatment for orthopedics, spine, general surgery, and gynecology patients. It provides treatments for back & spine, elbow, foot & ankle, gynaecology, hernias, hips, knees, lower GI / colorectal, shoulder, upper GI / biliary, urology, and wrist and hand, as well as surgeries, medical, and medico-legal services. The company was incorporated in 2001 and is based in Sheffield, United Kingdom.

Open the full interactive analysis →

Similar stocks

HCA Healthcare, Inc (H1CA34) -73% Fresenius SE (FSNUY) -25% 5225 (5225) -70% IHHHF (IHHHF) -57% Rede D'Or São Luiz S.A (RDOR3) -7% Tenet Healthcare Corporation (THC) +74%

Frequently asked questions

Is One Health Group (OHGR) undervalued?
As of Jun 24, 2026, our model estimates a fair value of p2.37 versus a price of p2.47 — about −4% (overvalued). Model-based estimate, not financial advice.
What is the fair value of OHGR?
Our 21-model fair value for One Health Group is p2.37 (as of Jun 24, 2026), built from audited fundamentals. The current price is p2.47.
What is the quality score of OHGR?
One Health Group has a Quality Score of 87/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.